Twin Health announced that it raised $140 million in a Series C financing round as it scales its service in the U.S. and globally. Mountain View, California-based Twin Health develops the Whole Body Digital Twin platform designed to help reverse and prevent chronic metabolic diseases while improving energy and health. According to a news release, […]
Funding Roundup
Thermo Fisher authorizes $3B in share repurchases
Thermo Fisher Scientific (NYSE:TMO) yesterday announced authorization for the repurchase of $3 billion in common stock shares. Waltham, Massachusetts-based Thermo Fisher’s board of directors approved the repurchase of $3 billion in shares of its common stock in the open market or in negotiated transactions, according to a news release. The authorization has no expiration date […]
Medicine-saving Nanodropper makes history in Minnesota Cup win
The Minnesota Cup has awarded its grand prize for innovative entrepreneurs to a student-led startup for the first time. Medical device developer Nanodropper took home top honors from the awards ceremony, held Monday at the University of Minnesota. “We have created an eyedrop bottle adaptor that will save billions in medication waste, one drop at […]
IVX Health raises $100M to accelerate expansion for infusion centers
IVX Health announced today that it completed a $100 million Series F minority investment round from Great Hill Partners. Nashville, Tennessee-based IVX plans to utilize the funding to accelerate its entry into new markets in 2022 and beyond in its effort to make its outpatient infusion centers the country’s preferred destination for pharmaceutical care for […]
Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes
The Novo Nordisk Foundation, the Broad Institute of MIT and Harvard have launched an initiative to gain insights into disease mechanisms. To accelerate efforts to mine genetic data for insights into mechanisms — and eventually rationally design treatments — the trio of entities launched the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease based […]
Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering
Virpax Pharmaceuticals (NSDQ:VRPX) announced today that it priced an underwritten public offering worth approximately $40 million. Berwyn, Pennsylvania-based Virpax’s offering includes 6.67 million shares of common stock priced at $6 per share, totaling just over $40 million before deducting underwriting discounts and offering expenses. Additionally, the company granted underwriters a 45-day option to purchase up […]
Impel NeuroPharma prices $45M offering following FDA approval for migraine treatment
Impel NeuroPharma (NSDQ:IMPL) announced that it priced an underwritten public offering of common stock worth $45 million. The offering includes 3 million shares of common stock priced to the public at $15 per share, with gross proceeds set to total $45 million before deducting underwriting discounts and commissions and other offering expenses payable by Impel […]
MiMedx confirms shelf registration to sell $350M
MiMedx (NSDQ:MDXG) announced today that its recently filed shelf registration with the SEC has become effective. Marietta, Georgia-based MiMedx last month filed the shelf registration statement on Form S-3 with the SEC with the intent to be allowed to sell up to $350 million in various types of securities over the next three years once […]
Eli Lilly to donate nearly $1M to Type 1 diabetes initiative
Eli Lilly (NYSE:LLY) announced today that it will commit nearly $1 million over the next three years toward helping children with Type 1 diabetes. Indianapolis-based Eli Lilly, in a joint effort with the Leona M. and Harry B. Helmsley Charitable Trust, seeks to promote greater access to care and resources while inspiring confidence for children […]
MiMedx files SEC shelf registration to sell up to $350M in securities
MiMedx (NSDQ:MDXG) announced today that it filed a shelf registration statement on Form S-3 with the SEC. Marietta, Ga.-based MiMedx, which develops AmnioFix, a micronized dehydrated human amnion/chorion membrane (dHACM) injection as regenerative medicine, will be allowed to sell up to $350 million in various types of securities over the next three years once the […]
